Is SILO or SKYE more undervalued in 2026?

CirclFi compares Silo Pharma, Inc. (SILO) and Skye Bioscience, Inc. (SKYE) using 13 institutional-grade valuation models. SILO has a Quality of Company score of 5.9/10 while SKYE scores 3.6/10.

Which is a better buy — SILO or SKYE?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SILO and SKYE valuations compare?

SILO at $0.42 and SKYE at $0.85 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SILO vs SKYE Valuation Comparison 2026 — Intrinsic Value Analysis

SILO

Biotechnology

Silo Pharma, Inc.

Quality

5.9

out of 10

Value Trap

LOW

Price

$0.42

Last close

Models

12/13

Active

SKYE

Biotechnology

Skye Bioscience, Inc.

Quality

3.6

out of 10

Value Trap

LOW

Price

$0.85

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	SILO Fair Value	SILO Upside	SKYE Fair Value	SKYE Upside
Bayesian DCF	Intrinsic	$0.24	-42.3%	$0.21	-74.8%
Earnings Power Value	Intrinsic	$0.39	-14.6%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.47	+10.9%	$1.84	+116.7%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SILO vs SKYE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SILO vs SKYE — Which Stock Is More Undervalued?

SILO scores higher with a 5.9/10 quality rating vs SKYE's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Silo Pharma, Inc. (SILO) and Skye Bioscience, Inc. (SKYE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SILO currently trades at $0.42 with a QOC of 5.9/10, while SKYE trades at $0.85 with a QOC of 3.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).